Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859697 | 0.92 | PKM (0.48) | PKMHTTTDP1ACHETSHR | |
| SCHEMBL5313256 | 0.92 | PKM (0.39) | PKMHTTTDP1ACHETSHR | |
| SCHEMBL5312949 | 0.88 | NPSR1 (0.48) | PKMTDP1ALDH1A1 | |
| SCHEMBL4851706 | 0.86 | PKM (0.46) | PKMHTTTDP1ACHEALDH1A1 | |
| SCHEMBL4862327 | 0.85 | PKM (0.50) | PKMHTTTDP1ACHEALDH1A1 | |
| SCHEMBL5313257 | 0.85 | PKM (0.41) | PKMHTTTDP1ACHETSHR | |
| SCHEMBL5335228 | 0.85 | DRD2 (0.35) | — | |
| SCHEMBL4859871 | 0.84 | PKM (0.43) | PKMHTTTDP1ACHETSHR | |
| SCHEMBL5308105 | 0.84 | SLC2A1 (0.43) | PKMTDP1ACHE | |
| Hydrochloric Acid SCHEMBL5315590 | 0.83 | SLC2A1 (0.42) | PKMTDP1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | REN, GLS, ATP6V1B1 | PKM 2400/4885HTT 2064/4885TDP1 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.